Zacks: Analysts Anticipate NuCana PLC (NCNA) to Announce -$0.26 Earnings Per Share

Wall Street analysts predict that NuCana PLC (NASDAQ:NCNA) will announce earnings of ($0.26) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for NuCana’s earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.23). The firm is expected to announce its next earnings results on Monday, January 1st.

Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for NuCana.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings data on Tuesday, August 28th. The company reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.19.

NCNA has been the subject of a number of research reports. Zacks Investment Research upgraded NuCana from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Thursday, October 4th. Piper Jaffray Companies initiated coverage on NuCana in a research note on Thursday, October 18th. They issued an “overweight” rating and a $36.00 price objective for the company. ValuEngine upgraded NuCana from a “hold” rating to a “buy” rating in a research note on Tuesday, October 2nd. Finally, Cowen reiterated a “buy” rating on shares of NuCana in a research note on Wednesday, August 29th.

Institutional investors have recently added to or reduced their stakes in the company. Rothschild Investment Corp IL purchased a new stake in shares of NuCana during the third quarter worth approximately $228,000. Woodford Investment Management Ltd raised its stake in shares of NuCana by 27.3% during the second quarter. Woodford Investment Management Ltd now owns 420,000 shares of the company’s stock worth $7,980,000 after purchasing an additional 90,000 shares during the last quarter. Asymmetry Capital Management L.P. raised its stake in shares of NuCana by 18.4% during the second quarter. Asymmetry Capital Management L.P. now owns 47,872 shares of the company’s stock worth $910,000 after purchasing an additional 7,424 shares during the last quarter. Alps Advisors Inc. raised its stake in shares of NuCana by 21.9% during the third quarter. Alps Advisors Inc. now owns 56,419 shares of the company’s stock worth $1,406,000 after purchasing an additional 10,150 shares during the last quarter. Finally, Baillie Gifford & Co. raised its stake in shares of NuCana by 2.2% during the second quarter. Baillie Gifford & Co. now owns 655,450 shares of the company’s stock worth $12,454,000 after purchasing an additional 14,330 shares during the last quarter. Institutional investors and hedge funds own 25.29% of the company’s stock.

Shares of NASDAQ NCNA opened at $19.20 on Friday. NuCana has a twelve month low of $9.32 and a twelve month high of $32.00.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.

Featured Article: Understanding each part of a balance sheet

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NuCana (NASDAQ:NCNA)

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply